(Q57639968)

4

0 references

author name string

Barry J. Byrne

1

0 references

Priya S. Kishnani

2

0 references

Wolfgang Müller-Felber

5

0 references

Suyash Prasad

6

0 references

Ans van der Ploeg

Molecular Genetics and Metabolism

7

0 references

publication date

May 2011

0 references

published in

0 references

volume

103

0 references

issue

1

0 references

page(s)

1-11

0 references

cites work

Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Late onset Pompe disease: Clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Pompe disease diagnosis and management guideline.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Pompe disease: a neuromuscular disease with respiratory muscle involvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

The natural course of non-classic Pompe's disease; a review of 225 published cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Clinical features of late-onset Pompe disease: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Sleep-disordered breathing and respiratory failure in acid maltase deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Course of disability and respiratory function in untreated late-onset Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: A case study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Visual hallucinations in a patient with adult onset acid maltase deficiency disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Enzyme replacement therapy in severe adult-onset glycogen storage disease type II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Progress in Enzyme Replacement Therapy in Glycogen Storage Disease Type II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

A randomized study of alglucosidase alfa in late-onset Pompe's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Disease severity in children and adults with Pompe disease related to age and disease duration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Screening of late-onset Pompe disease in a sample of Mexican patients with myopathies of unknown etiology: identification of a novel mutation in the acid alpha-glucosidase gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Standardisation of spirometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Diagnostic criteria for late-onset (childhood and adult) Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Diagnostic efficacy of the fluorometric determination of enzyme activity for Pompe disease from dried blood specimens compared with lymphocytes-possibility for newborn screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.02.004